Title:PEGylated Nanoliposomes Potentiated Oral Combination Therapy for Effective Cancer Treatment
Volume: 17
Issue: 9
Author(s): Archu Singh, Yub Raj Neupane, Bharti Mangla, Sadat Shafi and Kanchan Kohli*
Affiliation:
- Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi-110062,India
Keywords:
PEGylated liposome, combination therapy, oral drug delivery, breast cancer, exemestane, lycopene.
Abstract: The conventional treatment regimen for cancer with a single chemotherapeutic agent is far
behind the clinical expectations due to the complexity of cancer biology and is also associated with
poor Quality of Life (QOL) due to off-site toxicity and multidrug resistance. In recent years, nanopotentiated
combination therapy has shown significant improvement in cancer treatment via a synergistic
approach. However, being synthetic in nature, nanocarriers have been associated with the activation of
the Complement (C) activation system resulting in serious hypersensitivity reactions known as CActivation
Related Pseudoallergy (CARPA) effect once given via intravenous injection. On the other
hand, nanopotentiated oral drug delivery offers several advantages for the effective and safe delivery of
the drug to the target site. This hypothesis aims to put forward wherein Exemestane (chemotherapeutic
agent) and lycopene (herbal bioactive) co-laden into PEGylated liposomes and delivered to the breast
cancer via the oral route. PEGylation of the liposomes would prevent both molecules from the harsh
microenvironment of the Gastrointestinal Tract (GIT) and would eventually promote their intestinal
absorption via the lymphatic pathway to the systemic circulation. Lycopene being a potent antioxidant
and anti-cancer herbal bioactive would promote the therapeutic efficacy of the Exemestane via a synergistic
approach. This nanopotentiated oral combination therapy would pave the path for the safe and
effective treatment of cancer.